Previous 10 | Next 10 |
The FDA has accepted for review a marketing application from privately held Innocoll Holdings Limited seeking approval of Xaracoll (bupivacaine hydrochloride collagen-matrix implants) for the management of postsurgical pain after inguinal (groin) hernia surgery. The agency's action date is...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Noteworthy events during the week of March 22 - 28 for healthcare investors (some could be canceled/postponed due to COVID-19). More news on: Bristol-Myers Squibb Company, Zogenix, Inc., Heron Therapeutics, Inc., Healthcare stocks news, , Read more ...
Business disruptions due to COVID-19 represent a new risk for investors across all sectors. Expect to see language addressing this added to the risk factors section of 10-K annual reports filed with the Securities and Exchange Commission (SEC). For biotech and pharma companies, COVID-19 will im...
SAN DIEGO , Feb. 25, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced tha...
Investment Thesis Heron Therapeutics ( HRTX ) had a mixed year in 2019 and in my view some of the problems the company encountered are likely to continue to be felt through 2020 and perhaps beyond. This makes me concerned for the price of the company's stock. The three main issues the co...
Heron Therapeutics ( HRTX ) has been made its way onto my watch list a few times over the past couple of years and I have always found an excuse to hold off on starting a position. Admittedly, I haven’t checked on the ticker since HTX-011 received its CRL back in May of 2019. Now, I a...
SAN DIEGO , Feb. 19, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced tha...
SAN DIEGO , Feb. 18, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced tha...
Nothing provides greater stock price swings in the biotech sector than late-stage clinical trial results and drug approval decisions from the U.S. Food and Drug Administration. A recent research report from investment bank Jefferies (NYSE: JEF) listed key biotech events for the coming q...
News, Short Squeeze, Breakout and More Instantly...
Heron Therapeutics Inc. Company Name:
HRTX Stock Symbol:
NASDAQ Market:
Heron Therapeutics Inc. Website:
Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024 PR Newswire SAN DIEGO , July 30, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company...
Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System PR Newswire SAN DIEGO , July 15, 2024 /PRNewswire/ -- Heron Therapeutics, Inc....
Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN") PR Newswire -The U.S. Food and Drug Administration ("FDA") assigned a Prescription Drug User Fee Act ("PDUFA") goal date of September 23, 2024 ...